

03/20/00  
JC780 U.S. PTO

3-21-00

A

Attorney Docket No.: 3951.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL473440171US  
Date of Deposit March 20, 2000

JC530 U.S. PTO  
09/528644  
03/20/00

Sir:

This is a request for filing a **continuation** application under 37 C.F.R. 1.53(b)  
of

Applicant(s): Thim et al.

Title: Human Spasmolytic Polypeptide in Glycosylated Form

39 pages of specification 9 sheets of drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: $12 - 20 = 0 \times 18 =$	\$0
Independent Claims: $2 - 3 = 0 \times 78 =$	\$0
Total Fee:	\$690.00

Priority of Danish application no. 0068/93 filed on January 21, 1993 is claimed  
under 35 U.S.C. 119.


The benefit of application nos. 08/491,976 and 09/027,893 filed on August 2, 1995  
and February 23, 1998 in the U.S. and PCT/DK94/00037 filed January 20, 1994 via the  
PCT is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of  
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 20, 2000



---

Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**EXPRESS MAIL CERTIFICATE**

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
Title: Human Spasmolytic Polypeptide in Glycosylated Form  
Applicants: Thim et al.

Sir:

Express Mail Label No. EL473440171US

Date of Deposit : March 20, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Request Transfer of Computer Readable Sequence Listing
6. Information Disclosure Statement
7. PTO 1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly\_  
(Name of person mailing paper(s) or fee)

  
(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123